Treatment of High-Risk Neuroblastoma

For information about the treatments listed below, see the Treatment Option Overview section.

Children with newly diagnosed high-risk neuroblastoma usually receive treatment in three phases: induction, consolidation, and maintenance.

Treatment during induction may include:

Treatment during consolidation may include:

Treatment during maintenance may include monoclonal antibody therapy (dinutuximab), granulocyte-macrophage colony-stimulating factor (GM-CSF), and isotretinoin.

Treatment after maintenance may include eflornithine.

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.